VERAXA Biotech AG (NASDAQ: VRXA) announced the successful closing of its business combination with Voyager Acquisition Corp. (NASDAQ: VACH), marking the company's debut on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The transaction, which was previously announced, results in the formation of VERAXA Biotech AG, a biopharmaceutical company focused on developing next-generation antibody-based therapeutics.
The company's pipeline centers on its proprietary BiTAC platform, which includes bispecific T-cell engagers (BiTAC-TCE) and antibody-drug conjugates (BiTAC-ADC). The platform is designed to selectively target cancer cells while sparing healthy tissue, a key differentiator in the competitive oncology landscape. VERAXA recently presented preclinical data at the AACR Annual Meeting 2026 that demonstrated favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate, underscoring the platform's potential.
To support advancement toward clinical development, VERAXA secured significant financing. The company completed a $27.5 million senior secured note and entered into a securities purchase agreement for up to $50 million. These proceeds are expected to fund the progression of its BiTAC-TCE and BiTAC-ADC programs. The capital injection comes at a critical time as the company transitions from a preclinical to a clinical-stage entity.
The business combination with Voyager, a special purpose acquisition company focused on healthcare innovation, provides VERAXA with access to public markets and a stronger financial foundation. Voyager's team brings expertise in investing, operations, and medical innovation, which could accelerate VERAXA's growth trajectory. For more details on Voyager, visit https://www.voyageracq.com.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. The company's rigorous quality-by-design principles guide its rapid advancement of ADCs and BiTAC formats into clinical development. Regular updates are available at www.veraxa.com.
The listing on Nasdaq represents a milestone for VERAXA and the broader biotech sector, as investors gain exposure to a novel platform with potential in solid tumors and hematologic malignancies. For leaders in business and technology, the successful combination and financing highlight the continued appetite for innovative cancer therapies and the role of SPACs in bringing such companies to public markets. The full press release is available at https://ibn.fm/ka00j.
